What is the recommended management for sarcoidosis with pulmonary fibrosis?

Management of Sarcoidosis with Pulmonary Fibrosis

For patients with sarcoidosis and lung fibrosis at high risk of mortality or permanent disability, initiate glucocorticoid treatment to preserve lung function and quality of life, and if disease persists or glucocorticoid toxicity develops, add methotrexate as second-line therapy, followed by infliximab for refractory disease. 1

Algorithmic Treatment Approach

Step 1: Initial Assessment and Glucocorticoid Therapy

The 2021 ERS guidelines provide a strong recommendation to start glucocorticoid treatment in untreated patients with major pulmonary involvement who are at higher risk of future mortality or permanent disability 1. This applies directly to patients with pulmonary fibrosis, as fibrotic disease affects approximately 20% of sarcoidosis patients and carries significant morbidity and mortality 2, 3.

Initial dosing approach:

• Start prednisone 20-40 mg daily for 3-6 months 4
• Consider hydroxychloroquine in cases with hypercalcemia or skin disease 4
• The goal is to improve and/or preserve forced vital capacity (FVC) and quality of life 1

Critical caveat: Even low-dose prolonged prednisone causes substantial toxicity including weight gain, steroid-induced complications, and reduced quality of life 4. This necessitates early consideration of steroid-sparing agents rather than prolonged corticosteroid monotherapy.

Step 2: Adding Methotrexate (Second-Line)

Add methotrexate if:

• Disease continues despite glucocorticoids
• Unacceptable glucocorticoid side effects develop
• After 3-6 months of initial therapy 1, 4

The ERS guidelines provide a conditional recommendation for adding methotrexate in this scenario 1. While one randomized trial showed methotrexate didn't significantly improve FVC, it allowed significant prednisone reduction with lower weight gain 1. Multiple open-label studies demonstrate methotrexate is steroid-sparing and associated with improved lung function 1.

Important consideration: Methotrexate is the most widely studied second-line agent and better tolerated than other cytotoxic agents 4. Alternative second-line agents include azathioprine (equally effective as methotrexate), leflunomide, and mycophenolate mofetil 1.

Step 3: Adding Infliximab (Third-Line)

Add infliximab if:

• Disease progression despite glucocorticoids and methotrexate (or other immunosuppressives)
• Toxicity from second-line agents
• Severe or progressive disease 1, 4

The ERS guidelines provide a conditional recommendation for infliximab in patients who have failed glucocorticoids or other immunosuppressive agents 1. Two phase III randomized trials showed infliximab significantly improved FVC compared to prednisone, though absolute changes were small 1. Secondary endpoints included improved chest imaging and quality of life 1.

Duration considerations: Continue biologics for 2-3 years, as discontinuation after 6-12 months leads to disease relapse more than half the time 1, 4.

Special Considerations for Fibrotic Disease

Assessing Active Inflammation vs. Burnt-Out Fibrosis

This distinction is critical for treatment decisions 2. Fibrotic sarcoidosis may be:

• Active disease: Persistent granulomatous inflammation confirmed by 18F-FDG-PET scanning 2
• Burnt-out disease: Pure fibrosis without active inflammation

Anti-inflammatory/immunosuppressive treatment is only indicated when active granulomatous inflammation persists 3, 5. PET imaging helps rationalize long-term treatment decisions 1.

Antifibrotic Therapy

For progressive fibrotic disease, antifibrotic agents (pirfenidone and nintedanib) have shown benefit in slowing pulmonary function decline in randomized trials involving sarcoidosis-associated pulmonary fibrosis 5. However, the ERS guidelines note this requires further study 1. Consider antifibrotics in highly selected patients with progressive self-sustaining fibrosis 2, 3.

Managing Complications

Fibrotic pulmonary sarcoidosis commonly develops:

• Sarcoidosis-associated pulmonary hypertension (SAPH): Major cause of mortality requiring vasodilator therapy 2, 3, 5
• Chronic pulmonary aspergillosis: Requires antifungal antibiotics 2, 3
• Bronchiectasis: May need airway clearance and antibiotics 2

Lung Transplantation

Refer for transplant evaluation when:

• NYHA class III or IV symptoms
• Severe functional impairment despite maximal medical therapy
• Success rates similar to other lung transplant patients 5

Treatment Duration and Monitoring

Re-evaluate treatment need every 1-2 years 1. Relapse rates upon withdrawal are high:

• 20-80% relapse after 2 years of glucocorticoid withdrawal 1
• 80% require re-institution of therapy after stopping methotrexate 1

• 50% relapse after stopping infliximab 1

Taper to lowest effective dose rather than complete discontinuation in most cases 4.

Common Pitfalls

1. Prolonged corticosteroid monotherapy: Causes cumulative toxicity without addressing disease progression 4
2. Treating burnt-out fibrosis with immunosuppression: Exposes patients to toxicity without benefit when no active inflammation exists 2, 3
3. Premature treatment discontinuation: High relapse rates necessitate prolonged therapy 1
4. Missing pulmonary hypertension: Screen regularly as SAPH significantly impacts mortality 2, 3